Amgen CDR (CAD Hedged) (AMGN : TSX)
Common Stock
$27.57
CAD
+0.98 (3.69%)
Last updated: 2026-07-16
AMGN
Amgen CDR (CAD Hedged)
WealthAwesomePerformance
1 Day
+3.69%
1 Week
+2.11%
1 Month
+5.47%
YTD
+12.07%
Key Statistics
Market Cap
$188.79B
52W High
$28.99
52W Low
$20.03
P/E Ratio
24.25
50 Day MA
$25.86
200 Day MA
$26.15
Beta
-
Dividend Yield
35.04%
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/16/2026 | $27.26 | $27.57 | $27.26 | $27.57 | $27.57 | 9,371 |
| 7/15/2026 | $26.64 | $26.65 | $26.59 | $26.59 | $26.59 | 810 |
| 7/14/2026 | $26.40 | $26.41 | $26.39 | $26.41 | $26.41 | 1,270 |
| 7/13/2026 | $26.98 | $26.98 | $26.98 | $26.98 | $26.98 | 0 |
| 7/10/2026 | $26.98 | $26.98 | $26.95 | $26.95 | $26.95 | 270 |
| 7/9/2026 | $26.98 | $27.00 | $26.98 | $27.00 | $27.00 | 305 |
| 7/8/2026 | $27.38 | $27.38 | $27.24 | $27.37 | $27.37 | 47,182 |
| 7/7/2026 | $27.24 | $27.24 | $27.24 | $27.24 | $27.24 | 0 |
| 7/6/2026 | $27.88 | $27.88 | $27.00 | $27.25 | $27.25 | 713 |
| 7/3/2026 | $28.10 | $28.10 | $28.08 | $28.10 | $28.10 | 1,105 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
27.6%
Annualized
90-Day Vol
26.6%
Annualized
Trend (90d)
+23.3%
Annualized drift
90d Mean
C$29.97
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$28.35 | C$25.77 – C$31.18 |
| 60 trading days | C$29.15 | C$25.47 – C$33.35 |
| 90 trading days | C$29.97 | C$25.41 – C$35.34 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Amgen CDR (CAD Hedged)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- 10610.25%
- EPS (Diluted)
- 0.00
- Book Value
- -
💰 Recent Dividends
$0.1880
Ex: May 15, 2026
$0.1890
Ex: Feb 13, 2026
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE Report